Matrix metalloproteinase-9 concentrations in critically ill patients

K. A. Yassen, Helen Frances Galley, Nigel Robert Webster

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Matrix metalloproteinase-9 is involved in the processing of cytokines during sepsis. We studied 10 critically ill patients within 12 h of fulfilling the American Consensus Conference criteria for severe sepsis and compared the results with 12 critically ill non-septic control patients and eight healthy subjects. Total matrix metalloproteinase-9 concentrations were measured on days 1, 2 and 3. The median admission Acute Physiological and Chronic Health Evaluation II score was 19.5 (range 13-27) in the septic patients and 20.5 (range 7-28) in the non-septic patients. Four patients from each group died within 28 days. Matrix metalloproteinase-9 concentrations were elevated significantly in both groups of patients compared with healthy subjects (p = 0.0004) but there was no difference between patients with and without sepsis. Matrix metalloproteinase-9 levels did not change with time, and there was no difference between survivors and those who died. We conclude that matrix metalloproteinase-9 represents a non-specific market of systemic inflammation.

Original languageEnglish
Pages (from-to)729-732
Number of pages3
JournalAnaesthesia
Volume56
Issue number8
DOIs
Publication statusPublished - 2001

Keywords

  • critical care, sepsis
  • metalloproteinase
  • cytokine
  • TUMOR-NECROSIS-FACTOR
  • SEPTIC SHOCK
  • ALPHA
  • MORTALITY
  • DISEASE

Cite this

Matrix metalloproteinase-9 concentrations in critically ill patients. / Yassen, K. A.; Galley, Helen Frances; Webster, Nigel Robert.

In: Anaesthesia, Vol. 56, No. 8, 2001, p. 729-732.

Research output: Contribution to journalArticle

Yassen, K. A. ; Galley, Helen Frances ; Webster, Nigel Robert. / Matrix metalloproteinase-9 concentrations in critically ill patients. In: Anaesthesia. 2001 ; Vol. 56, No. 8. pp. 729-732.
@article{6c4b8ab1854045c0902a78513f75b0d1,
title = "Matrix metalloproteinase-9 concentrations in critically ill patients",
abstract = "Matrix metalloproteinase-9 is involved in the processing of cytokines during sepsis. We studied 10 critically ill patients within 12 h of fulfilling the American Consensus Conference criteria for severe sepsis and compared the results with 12 critically ill non-septic control patients and eight healthy subjects. Total matrix metalloproteinase-9 concentrations were measured on days 1, 2 and 3. The median admission Acute Physiological and Chronic Health Evaluation II score was 19.5 (range 13-27) in the septic patients and 20.5 (range 7-28) in the non-septic patients. Four patients from each group died within 28 days. Matrix metalloproteinase-9 concentrations were elevated significantly in both groups of patients compared with healthy subjects (p = 0.0004) but there was no difference between patients with and without sepsis. Matrix metalloproteinase-9 levels did not change with time, and there was no difference between survivors and those who died. We conclude that matrix metalloproteinase-9 represents a non-specific market of systemic inflammation.",
keywords = "critical care, sepsis, metalloproteinase, cytokine, TUMOR-NECROSIS-FACTOR, SEPTIC SHOCK, ALPHA, MORTALITY, DISEASE",
author = "Yassen, {K. A.} and Galley, {Helen Frances} and Webster, {Nigel Robert}",
year = "2001",
doi = "10.1046/j.1365-2044.2001.02083.x",
language = "English",
volume = "56",
pages = "729--732",
journal = "Anaesthesia",
issn = "0003-2409",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Matrix metalloproteinase-9 concentrations in critically ill patients

AU - Yassen, K. A.

AU - Galley, Helen Frances

AU - Webster, Nigel Robert

PY - 2001

Y1 - 2001

N2 - Matrix metalloproteinase-9 is involved in the processing of cytokines during sepsis. We studied 10 critically ill patients within 12 h of fulfilling the American Consensus Conference criteria for severe sepsis and compared the results with 12 critically ill non-septic control patients and eight healthy subjects. Total matrix metalloproteinase-9 concentrations were measured on days 1, 2 and 3. The median admission Acute Physiological and Chronic Health Evaluation II score was 19.5 (range 13-27) in the septic patients and 20.5 (range 7-28) in the non-septic patients. Four patients from each group died within 28 days. Matrix metalloproteinase-9 concentrations were elevated significantly in both groups of patients compared with healthy subjects (p = 0.0004) but there was no difference between patients with and without sepsis. Matrix metalloproteinase-9 levels did not change with time, and there was no difference between survivors and those who died. We conclude that matrix metalloproteinase-9 represents a non-specific market of systemic inflammation.

AB - Matrix metalloproteinase-9 is involved in the processing of cytokines during sepsis. We studied 10 critically ill patients within 12 h of fulfilling the American Consensus Conference criteria for severe sepsis and compared the results with 12 critically ill non-septic control patients and eight healthy subjects. Total matrix metalloproteinase-9 concentrations were measured on days 1, 2 and 3. The median admission Acute Physiological and Chronic Health Evaluation II score was 19.5 (range 13-27) in the septic patients and 20.5 (range 7-28) in the non-septic patients. Four patients from each group died within 28 days. Matrix metalloproteinase-9 concentrations were elevated significantly in both groups of patients compared with healthy subjects (p = 0.0004) but there was no difference between patients with and without sepsis. Matrix metalloproteinase-9 levels did not change with time, and there was no difference between survivors and those who died. We conclude that matrix metalloproteinase-9 represents a non-specific market of systemic inflammation.

KW - critical care, sepsis

KW - metalloproteinase

KW - cytokine

KW - TUMOR-NECROSIS-FACTOR

KW - SEPTIC SHOCK

KW - ALPHA

KW - MORTALITY

KW - DISEASE

U2 - 10.1046/j.1365-2044.2001.02083.x

DO - 10.1046/j.1365-2044.2001.02083.x

M3 - Article

VL - 56

SP - 729

EP - 732

JO - Anaesthesia

JF - Anaesthesia

SN - 0003-2409

IS - 8

ER -